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 This study presents a systematic review of the published literature on possible long-term 
adverse effects after extracorporeal shock wave lithotripsy (ESWL). While published 
disagreement exists, this review finds that previous evidence supporting an association 
between ESWL and long-term adverse effects is weak, and that the majority of studies show 
no evidence for any increase in post-ESWL incidence of arterial hypertension (24 of 30 
studies), diabetes mellitus (4 of 6 studies), kidney dysfunction (14 of 14 studies), or infertility 
(2 of 2 studies). Currently, no strong evidence exists to support the hypothesis that ESWL 
causes long-term adverse effects. 
 
 Introduction 
Extracorporeal shock wave lithotripsy (ESWL) is a noninvasive treatment option for nephro- 
and ureterolithiasis. Since its introduction in the 1980s, millions of patients have benefited, 
and ESWL quickly became the gold standard therapy for nephro- and ureterolithiasis. Known 
short-term side effects of ESWL are renal hematoma, infectious complications, “steinstrasse” 
(“stone street”) blockage caused by remaining stone fragments, renal colic, or regrowth of 
urinary calculi.1 However, long-term adverse effects (LAE) have not been thoroughly 
evaluated to date, and several authors have reported contradictory results. Potential LAE of 
ESWL include arterial hypertension (HTN), diabetes mellitus (DM), chronic kidney disease 
(CKD), and decreased fertility (FERT). Because no large prospective studies have been 
conducted to observe LAE after ESWL, we synthesize the published evidence regarding the 
four most discussed LAE in this systematic review. 
Methods 
This systematic review was conducted in accordance with the recommendations of the 
PRISMA statement2  and a recent publication about reporting adverse events in systematic 
reviews.3 
Literature search 
We conducted a literature search on December 19, 2013 using the following databases:  
Embase, Scopus, Cochrane, Medline, and Web of Science. For our literature research we used 
combinations of search terms related to “hypertension,” “diabetes mellitus,” “kidney function 
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deterioration,” fertility,” and “adverse effects,” in various combinations with “long-term,” 
“nephro- and ureterolithiasis,” and “lithotripsy.”  The detailed search strategy used to query 
the Medline database is shown in Appendix 1. Additionally, the reference lists of all of the 
identified publications were searched manually to identify further relevant studies describing 
long-term adverse effects of ESWL. 
Eligibility criteria 
Peer-reviewed studies reporting at least one of the four adverse effects of interest (HTN, DM, 
CKD, FERT) were eligible for inclusion in this review. We excluded studies with fewer than 
30 patients and those with a follow-up period of less than one year. 
Study selection 
Duplicate articles were filtered using the “close match function” within the Endnote citation 
management software and subsequently two authors (CDF, BK) performed additional manual 
deduplication. The same two authors screened the titles and abstracts independently to select 
publications compliant with the eligibility criteria and came to a consensus about inclusion of 
studies. 
Data extraction and synthesis 
A data extraction sheet (based on the data extraction template from the Cochrane Consumers 
and Communication Review Group) was developed and further adapted after pilot testing on 
five randomly selected eligible studies. Data were collected on study design, length of 
follow-up, patient characteristics, outcome assessment methods, and outcome definitions for 
HTN, DM, CKD, and FERT. One investigator (CDF) extracted the data and a second 
investigator (BK) reviewed the extracted data. Disagreements were discussed and resolved by 
consensus or by third-party arbitration (JS). 
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Quality assessment 
Study quality was determined using the Scottish Intercollegiate Guidelines Network (SIGN) 
methodology checklist for cohort studies and randomized controlled trials.4 Overall study 
quality and bias risk were rated according to the SIGN recommendations. Quality ratings 
were assigned as follows: high, indicating that most criteria were fulfilled and the study 
conclusions are very unlikely to be altered; moderate, that some criteria were fulfilled and, in 
cases where the criteria were not fulfilled, the study conclusions are unlikely to be altered; 
and low, that few or no of the criteria were fulfilled, and conclusions are likely to be altered. 
Results  
Study selection 
The complete study selection process is illustrated in Figure 1. After deduplication, we 
retrieved 889 citations. Of these, 827 studies were discarded after review of the abstracts 
because they did not fulfill the eligibility criteria. The full text of 62 publications was 
reviewed in detail, and a final total of 39 studies matched the inclusion criteria.  
Study characteristics 
The selected studies were published between 1988 and 2013. Two were randomized 
controlled trials (RCT) and 37 were cohort studies. The number of patients included ranged 
from 30 to 1758 in the ESWL study groups. Trial and patient characteristics are summarized 
in Appendix 2. 
Quality of the included studies 
The SIGN quality was rated high in 3 studies (8%), moderate in 9 studies (23%), and poor in 
27 studies (69%). A detailed summary of the assessment is reported in Appendix 3. 
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Outcomes of primary interest  
Arterial hypertension (HTN) 
Of the 30 included studies reporting on the incidence of HTN after ESWL, two were RCTs 
and 28 were cohort studies. All were published between 1988 and 2012. The number of 
patients treated with ESWL in each study ranged from 35 to 1758, and median follow-up 
periods ranged from 12 to 240 months. We found 17 studies describing patients with HTN 
without any comparison to a control group. Two studies compared the HTN prevalence with a 
healthy population, whereas the remaining 11 studies matched the ESWL-treated patients 
with an untreated nephro-/ureterolithiasis population. We identified 10 different blood 
pressure cut-off levels used to define HTN. In 6 out of 30 studies, the authors concluded that 
ESWL might be causal for new-onset HTN. No evidence for an increase in the incidence of 
HTN was reported in the remaining 24 (80%) publications (see Fig. 2).  Data were not pooled 
in a meta-analysis because of heterogeneous definitions of HTN and data acquisition. For 
individual study results, see Appendix 2, Tables 1 and 2. 
Diabetes mellitus (DM) 
All six included studies were cohort studies, which were published between 2008 and 2013. 
The number of ESWL-treated patients ranged from 70 to 772. Four studies incorporated a 
control group, whereas two describe only a single ESWL cohort. One study retrieved 
information from an epidemiological register, two studies assessed serum glucose levels, and 
three studies asked physicians or patients about a potential diagnosis of DM and prescribed 
anti-diabetic therapy. Follow-up periods ranged from 5 to 20 years. In two studies, the 
authors concluded that ESWL might be causal for new-onset DM, whereas four studies found 
no evidence for an increase in the incidence of DM. Due to heterogeneous control groups and 
use of different methods to obtain the DM status of the patients, study data were not pooled in 
a meta-analysis. For individual study results, see Appendix 2, Tables 3 and 4. 
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Chronic kidney disease (CKD)  
Of the 14 included studies regarding kidney failure, we retrieved seven retrospective and 
seven prospective cohort studies, which were published between 1992 and 2012. Median 
follow-up periods ranged from 15 months to 17 years. One study compared the ESWL cohort 
with a cohort treated with percutaneous-nephrolithotomy (PNL), whereas another study 
compared patients with ESWL-treated renal stones to patients with  ESWL-treated ureteral 
stones. One study compared patients with ESWL-treated stones to a cohort of asymptomatic 
stone carriers. Eleven studies had no control groups. Eleven studies retrieved information 
about kidney function by looking at laboratory findings, one study by asking the patient about 
any kidney problems, and two studies did not report precisely how kidney function was 
assessed. All 14 studies concluded that there is no evidence for an increase in the incidence of 
CKD after ESWL. Due to the heterogeneous methods used to obtain the patients’ kidney 
function status and varied definitions of kidney function, data were not pooled in a meta-
analysis. For individual study results, see Appendix 2, Table 5. 
Decreased fertility (FERT) 
We were able to identify two retrospective studies focusing on female infertility but none 
focusing on male infertility. Vieweg5 asked 67 women about secondary sterility, 
contraception, miscarriages, and malformations in their newborns. Of the 67 female patients 
who answered the questionnaire, only 10 patients were actually trying to conceive after 
ESWL. Similarly, Erturk6 sent out a questionnaire to 39 patients, of which ten mothers 
reported to have successfully delivered 11 babies in total. For individual study results see 
Appendix 2, Table 6. 
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Discussion 
From animal studies, in vitro studies, and imaging studies, we have evidence that ESWL can 
cause histological renal changes, even at low doses, and that it may result in an increase in 
mean arterial blood pressure by damaging the kidney7,8 and other intra-abdominal organs.9 
Uncertainty prevails regarding long-term adverse effects. 
Arterial hypertension (HTN) 
While treating renal calculi with ESWL, the kidneys are directly exposed to shockwaves. 
Shockwaves cause shear stress on the urinary calculi, but as a potential side effect, 
shockwaves might also damage kidney tissue and could therefore lead to HTN. 
In our review, only six out of 30 studies concluded that ESWL might lead to HTN. Of these 
six studies, three had no controls or comparison of ESWL-treated patients with an average 
population. A study by Krambeck et al. found an ESWL-related increase in HTN rate in 
200610 but the authors subsequently published the results of a study focusing on a different 
cohort with an incidence of HTN not different compared to persons without prior ESWL.11 
While comparing PNL and ESWL, Lingeman et al. found a lower annual incidence of HTN 
among ESWL patients compared to non-ESWL patients, yet also reported a rise in diastolic 
blood pressure.12  The evidence presented in the six cohort studies that found an increased 
new-onset HTN rate after ESWL is weaker compared to that in the other 24 studies, including 
two RCTs, which found no association (see Appendix 2, Tables 1 and 2). 
A systematic review with a meta-analysis regarding the incidence of HTN after ESWL was 
published recently by Yu.13 Despite stating an intention to follow the PRISMA guidelines, no 
literature research protocol was published, and it seems that the search was performed with 
very few key words. Perhaps due to our extended research protocol, our study included 19 
additional studies compared to the set evaluated by Yu.13 In contrast to the approach taken by 
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Yu,13 we waived a meta-analysis because we detected two common pitfalls affecting most of 
the included studies. First, variation in the definition of HTN cut-off values can change the 
annualized incidence rate of HTN from 6% to 14%.14 We note that in the included studies a 
total of 10 different blood pressure cut-off levels were used to define HTN. Second, the data 
sources and methods used to obtain blood pressure reading or diagnostic codes were very 
heterogeneous. In our opinion, the above-described heterogeneity in both the definitions of 
HTN and the methods to obtain the HTN status make a meta-analysis unadvisable. 
Diabetes mellitus (DM) 
The pancreas lies in the retroperitoneum and might be exposed to shockwaves with resulting 
tissue damage during ESWL due to its proximity to the kidneys. Two studies indicated an 
increase in DM rate after ESWL. The first study, by Kazemi et al., found an 8.1% diabetes 
prevalence after ESWL in a cohort of 307 patients15. This prevalence has to be interpreted 
with caution because no control group was observed. Thus, it remains possible that some 
metabolic dysfunction resulting in nephro- and ureterolithiasis and DM might result in the 
higher DM prevalence, rather than the ESWL therapy itself16. The second study, published by 
Krambeck et al in 2006,10 describes a 16.8% incidence of new-onset DM after ESWL, but the authors 
subsequently published the results of a study focusing on a different cohort with an incidence 
of DM not different compared to persons without prior ESWL.17 With only six relevant 
studies, none of them RCT, it is not possible to make a conclusive statement about whether 
ESWL might cause DM. 
Chronic kidney disease (CKD)  
The kidneys are directly exposed to shockwaves when urinary calculi lie within the renal 
pelvis. Short-term adverse effects after ESWL have been described in detail.1 However, it is 
unclear whether the observed acute tissue damage may lead to chronic kidney function 
deterioration. None of the studies that we reviewed found evidence for an increase in the 
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incidence of kidney function deterioration after ESWL. Therefore, based on the existing 
evidence, we conclude that ESWL is not seen to influence kidney function in a negative 
manner. However, the current literature is limited and therefore cannot give a final statement 
about possible association of ESWL with kidney failure. 
Fertility (FERT) 
The uteri/adnexa, their vascular supply, and the vascular supply of the testicles are directly 
exposed to shockwaves when urinary calculi lie in the distal ureter, therefore raising the 
question of whether ESWL may compromise male or female fertility. In a systematic review 
including clinical short term studies, in vitro studies, and animal studies, Philippou et al.18 
could not provide a final statement about male infertility as no studies with long-term follow-
up were available at the time. In our current literature research, we identified two studies5,6 
focusing on female fertility. In both studies, only 10 patients had attempted to become 
pregnant, which is an insufficient sample size to show any effect of ESWL on fertility. 
Furthermore, fertility is difficult to define and to assess in a retrospective manner.  Therefore, 
no conclusion about the possible influence of ESWL on fertility can be drawn from the 
identified studies.  
Limitations 
The poor methodological quality of the published studies may result in bias. For example, the 
vast majority of the included studies are retrospective studies, which are prone to bias. 
Furthermore, most studies do not compare the incidence of LAE between the ESWL patients 
and an adequate control group. Our search criteria were designed and reviewed by clinicians 
and librarians and were included in our peer-reviewed protocol. However, it is possible that 
not all potentially relevant studies were identified due to undetected flaws in our search 
strategy, and thus this would have to be classified as a potential source of bias. 
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Conclusions  
Currently, no strong evidence supports the hypothesis that ESWL causes long-term adverse 
effects. Most of the relevant studies from the published literature have to be interpreted with 
caution because study designs are mostly retrospective, with inadequate control groups, small 
sample sizes, and short follow-up periods. New studies addressing the above-mentioned 
weaknesses are needed to reach a final conclusion about long-term adverse effects after 
ESWL. 
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Figure 1: Selection of extracorporeal shock wave lithotripsy (ESWL) studies. From the 
initial 889 records that we initially identified, we included 39 studies after the selection 
process, as illustrated above.  
Appendix 2 
Table 1 Studies suggesting no association between ESWL and an increase in the incidence of arterial hypertension 
First 
Author 
Study 
design 
Follow-up 
time in 
months 
(mean or 
median) 
Control 
group 
Identification 
of patients with 
arterial 
hypertension 
pre= before ESWL 
post= after ESWL 
Definition of arterial 
hypertension 
Results/ Conclusion 
Liedel 1 Retrospect
ive cohort 
40 Other group 
of patients 
treated with  
ESWL 
Pre: chart 
review 
Post: patient 
reported 
RR >160/95 mmHg or 
prescribed 
antihypertensive 
therapy  
No evidence for an ESWL-
related increased risk of 
hypertension; no indication for 
any deterioration of renal 
function 
Montgom
ery 2 
Retrospect
ive cohort 
29 
(SD 8.4)  
(range 12-
44) 
None Pre: chart 
review 
Post: Reported 
by 
physicians  
Systolic RR > age+100 
mmHg, diastolic RR 
>95mmHg 
No change in the mean arterial 
pressure  
Nijman 3 Prospectiv
e cohort 
24 
(range 13-
40) 
None Not reported Not reported Hypertension did not occur in 
any patient during follow-up 
Puppo 4 Retrospect
ive cohort  
average not 
reported 
(range 12-
36) 
None Pre: chart 
review 
Post: reported 
by 
physician  
RR > 130/95 mmHg for 
women, >140/90 
mmHg for men 
younger 45y and 
>150/95 mmHg older 
45y 
No evidence for an increase in 
the incidence of arterial 
hypertension 
Mays 5 Prospectiv
e cohort 
24 PNL Post: Reported 
by patients 
Not reported new medical problem (…) which 
could be potentially been 
associated with their renal 
treatment was found 3% in the 
PNL, and in 2% in the ESWL 
group 
Yokoyama 
6 
Retrospect
ive cohort 
18 
(SD 17)  
None Pre: chart 
review 
Post: Not 
reported 
RR >160/95 mmHg No evidence for an increase in 
the incidence of arterial 
hypertension 
Zanetti 7 
 
Prospectiv
e cohort 
29 None Pre: measured 
by physician 
Post: measured 
by physician 
RR >160/95 mmHg No evidence for an increase in 
the incidence of arterial 
hypertension 
Carlson 8 Retrospect
ive cohort 
40 
(range 12-
56) 
PNL Pre: chart 
review 
Post: measured 
by physician 
Not reported No evidence for an increase in 
the incidence of arterial 
hypertension 
Claro 9 Prospectiv
e cohort 
22 
(range 5-41) 
None Pre: measured 
by physicians 
Post: measured 
by physicians 
Diastolic RR 
>90mmHg 
No evidence for an increase in 
the incidence of arterial 
hypertension 
Simon 10 Retrospect
ive cohort 
24 None Pre: measured 
by physicians 
Post: telephone 
interview with 
patient or 
physician 
Not reported No evidence for an increase in 
the incidence of arterial 
hypertension 
Sarica 11 Prospectiv
e cohort 
33 
(range 30-
39) 
None Pre: measured 
by physicians 
Post: measured 
by physician 
Not reported No evidence for an increase in 
the incidence of arterial 
hypertension 
Jewett 12 RCT 12 asymptomat
ic stone 
carriers 
Pre: measured 
by physicians 
Post: measured 
by physicians 
Diastolic RR 
>100mmHg 
No evidence for an increase in 
the incidence of arterial 
hypertension 
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Barbosa 1 Y N NA N 73
% 
NA Y NA NA NA N N N N - N Y 
Brinkmann 2 Y NA NA Y 16
% 
N Y NA Y Y N N N N - Y Y 
Carlson 3 Y N NA Y 45
% 
N Y NA NA NA N N N N - Y Y 
Chew 4 Y N N Y 42
.7
% 
NA Y NA NA N N N N N - Y Y 
Claro 5 Y Y N Y 16
% 
N Y NA NA Y Y Y N N + Y Y 
Cogain 6 Y Y NA Y N
A 
NA Y NA NA NA NA N N N + Y Y 
Eassa 7 Y NA N Y 16
% 
N Y NA NA Y NA N N N + Y Y 
El-Assmy 8 Y NA N Y 47
% 
NA N NA NA Y N N N N - Y Y 
El-Assmy 9 Y NA N Y 31
% 
N N NA NA Y N N N N - Y Y 
El-Nahas 10 Y NA N Y 30
% 
N Y NA NA N N N N N - Y Y 
Erturk 11 Y NA N N 44
% 
N N NA NA N N N N N - N Y 
Graff 12 Y NA N N 43
% 
N N NA NA N N N N N - Y Y 
Janetschek 13 Y NA N Y 25
% 
N Y NA NA Y N N N N - Y Y 
Kazemi 14 Y NA Y Y 78
% 
N Y NA NA Y Y N N N - Y Y 
Knapp 15 Y NA N Y 0
% 
NA Y NA NA Y Y N N N + Y Y 
Krambeck 16 Y Y Y Y 41
% 
Y Y NA NA Y N N Y Y + Y Y 
Krambeck 17 Y Y NA Y N
A 
NA Y NA NA NA NA N N Y + Y Y 
Lingeman 18 Y Y Y Y 27
% 
N Y NA NA Y Y Y Y Y + Y Y 
Liedl 19 Y N N N 35
.4
% 
N Y NA NA N Y N N N - N Y 
Mays 20 Y N NA N 45
% 
N N N N Y N Y N N - N Y 
Montgomery 21 Y NA NA Y 22
% 
N Y NA NA N N N N Y - N Y 
Nijman 22 Y NA N NA 0
% 
N N NA NA N N N N N - N Y 
Perry 23 Y NA N N 54
% 
N N NA NA N N N Y N - N Y 
Puppo 24 Y NA N Y 0
% 
NA Y NA NA N N N N N - N Y 
Protogerou 25 Y NA N Y 0
% 
N Y N N Y Y Y N N ++ Y Y 
Ramakrishnan 
26 
Y NA N Y 0
% 
N N NA NA N N N N N - Y Y 
Sarica 27 Y NA N Y 0
% 
N Y NA NA Y N N N N - N Y 
Sato 28 Y Y Y Y 70
% 
N Y NA NA N N N Y Y + Y Y 
Simon 29 Y NA NA N 5
% 
N Y NA NA N N N N N - N Y 
Strohmaier 30 Y Y N Y 0
% 
N Y N N Y Y Y N N + Y Y 
Traxer 31 Y NA N Y 0
% 
N N NA NA N N N N N - N Y 
Vieweg 32 Y NA NA N 20
% 
N N NA NA N N N N N - N Y 
Williams 33 Y NA NA Y 39
% 
N Y NA NA Y N N N N - N Y 
Yokoyama 34 Y NA N Y 0
% 
N Y NA NA Y N N N N - N Y 
Yoo 35 Y Y Y Y 0
% 
N Y N N Y Y N N N - Y Y 
Zanetti 36 Y NA N Y 28
% 
N Y NA NA Y Y N N N - Y Y 
Zanetti 37 Y NA N Y 0
% 
NA Y NA NA N N Y N N - N Y 
Table 1: Study quality determined using the Scottish Intercollegiate Guidelines Network (SIGN) methodology checklist for cohort 
studies  
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Table 2: Study quality was determined using the Scottish Intercollegiate Guidelines Network (SIGN) methodology checklist for 
randomized controlled trials 
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Traxer 13 Prospectiv
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Mean not 
reported 
(range 6-96) 
None Not reported Not reported No evidence for an increase in 
the incidence of arterial 
hypertension 
Elves 14 RCT 26 
(range 12-
60) 
asymptomat
ic stone 
carriers  
Pre: measured 
by physicians  
Post: measured 
by physician 
systolic RR 
>160mmHg 
or diastolic RR > 
90mmHg 
No evidence for an increase in 
the incidence of arterial 
hypertension 
Strohmaie
r 15 
Prospectiv
e cohort 
24 Only 
ureteral 
stones 
Pre: measured 
by physicians 
Post: measured 
by physicians 
Not reported “No difference between renal 
and uretheral stones, or 
between the ESWL treatment 
and the other groups” 
Brinkman
n 16 
Prospectiv
e cohort 
45 None Pre: measured 
by physicians 
Post: measured 
by physicians 
Not reported No evidence for an increase in 
the incidence of arterial 
hypertension 
Protogeru 
17 
Prospectiv
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12 Distal 
ureteral 
stones 
treated with 
ESWL, or 
URS 
Pre: 24h RR 
measurement 
Post: 24h RR 
measurement 
Mean 24h RR value > 
125/80 mmHg 
“ESWL may be responsible for a 
drop in blood pressure” 
Ramakris
hnan 18 
Prospectiv
e cohort 
90 None Pre: measured 
by physicians  
Post: measured 
by physicians 
Not reported 1 of 39 children developed 
arterial hypertension 
Eassa 19 Prospectiv
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(range 18-
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None Pre: measured 
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reported by 
patients 
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by physicians/ 
reported by 
patients 
RR >140/90 mmHg  
or prescribed 
antihypertensive 
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hypertension 
El-Assmy 
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Retrospect
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(SD 42) 
(range 12-
192) 
None Pre: measured 
by physicians 
Post: measured 
by physicians 
Not reported No evidence for an increase in 
the incidence of arterial 
hypertension 
Sato 21 Retrospect
ive cohort 
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(range 132-
264) 
Ureteral 
stones 
treated with 
ESWL 
Patient reported Diagnosis of arterial 
hypertension and 
prescribed 
antihypertensive 
therapy 
No evidence for an increase in 
the incidence of arterial 
hypertension 
Chew 22 Retrospect
ive cohort 
240 Canadian 
community 
health 
survey 
Post: reported 
by patients 
Diagnosis of arterial 
hypertension and 
prescribed 
antihypertensive 
therapy 
No evidence for an increase in 
the incidence of arterial 
hypertension 
Krambeck 
23 
Retrospect
ive cohort 
104 
(range 4-
300) 
Non 
surgically 
managed 
urolithiasis 
patients 
Based on ICD 
entries of 
patients in 
database 
Not reported Failed to identify an association 
between ESWL and HTN 
El Nahas 
24 
Retrospect
ive cohort 
62 
(SD 43) 
(range 25-
210) 
None Pre: measured 
by physicians 
Post: measured 
by physicians 
Diastolic RR > 95 
centile 
No evidence for an increase in 
the incidence of arterial 
hypertension 
 
 
Table 2 Studies suggesting an association between ESWL and an increase in the incidence of arterial hypertension 
First 
Author 
Study 
design 
Follow-up 
time in 
months 
(mean or 
median) 
Control 
group 
Identification 
of patients with 
arterial 
hypertension 
pre= before ESWL 
post= after ESWL 
Definition of arterial 
hypertension 
Results/ Conclusion by authors 
Williams 
25 
Retrospect
ive cohort 
17-21 None Pre: chart 
review 
Post: Reported 
by 
physicians 
RR > 150/95 mmHg Statistical increase in diastolic 
and systolic blood pressure after 
ESWL “8% of patients developed 
hypertension” 
Lingema
nn 26 
Retrospect
ive cohort  
96 
(SD 9)  
PNL, URS Pre: chart 
review 
Post: Reported 
by 
physicians 
prescribed 
antihypertensive 
therapy or diastolic 
RR >90mmhg 
Statistically significant rise in 
diastolic blood pressure; but no 
evidence in the increase of the 
incidence of arterial hypertension 
Knapp 27 Prospectiv
e cohort 
mean not 
reported 
(range 17-
23) 
None Pre: Measured 
by 
physicians 
Post: Measured 
by 
physicians 
RR >145/95mmhg Compared with normal 
prevalence of arterial 
hypertension in Austria (…) the 
risk of risk of hypertension is 
increased in older patients 
Janetsch
ek 28 
Prospectiv
e cohort 
26 
(range 18-
31) 
None Post: Measured 
by 
physicians 
systolic  RR >140 
mmhg 
and/or diastolic RR 
>90 mmhg 
There is some evidence that in 
patients older than 60 years 
ESWL is associated with new 
onset of arterial hypertension  
Krambec
k 29 
Retrospect
ive cohort 
228 Non 
surgically 
managed 
Post: Reported 
by 
Diagnosis of arterial 
hypertension and 
prescribed 
New onset hypertension 36.4% in 
the ESWL compared to 27.4% in 
the control group 
urolithiasis 
patients 
patients antihypertensive 
therapy 
ESWL is associated with the 
development of HTN 
Barbosa 
30 
Retrospect
ive cohort 
72 Normal 
Population 
from 
NHANES 
database 
Post: Reported 
by patients 
Diagnosis of arterial 
hypertension and 
prescribed 
antihypertensive 
therapy 
The prevalence of arterial 
hypertension in the ESWL group 
increased from 26.7% before to 
37.8% after ESWL compared to a 
matched control group 28% 
before and 32.5% after ESWL 
ESWL is associated with the 
development of HTN 
 
 
 
 
Table 3 Studies suggesting no association between ESWL and an increase in the incidence of diabetes mellitus 
First 
Author 
Design Follow-up time 
in months 
(mean or 
median) 
Reference 
group 
Identification of 
patients with 
diabetes mellitus 
pre= before ESWL 
post= after ESWL 
Results/ Conclusion by authors 
Sato 21 Retrospect
ive cohort 
204 
(range 132-264) 
Ureteral stones 
treated with 
ESWL 
reported by patients No evidence for an increase in the 
incidence of diabetes mellitus 
Chew 22 Retrospect
ive cohort 
240 Canadian 
community 
health survey 
reported by patients No evidence for an increase in the incidence 
of diabetes mellitus 
Cogain 
31 
Retrospect
ive cohort 
104 
(range 36-276) 
Non-SWL 
urolithiasis 
patients 
Post: disease codes 
from an 
epidemiological 
No evidence for an increase in the incidence 
of diabetes mellitus 
register 
El-Nahas 
24 
Retrospect
ive cohort 
62.4  
(SD 43) 
(range 25-210) 
None Post: Blood serum 
glucose levels 
No evidence for an increase in the incidence 
of diabetes mellitus 
 
Table 4 Studies suggesting an association between ESWL and an increase in the incidence of diabetes mellitus 
First 
Author 
Design Follow-up 
time in 
months 
(mean or 
median) 
Reference group Identification of patients 
with diabetes mellitus 
pre= before ESWL 
post= after ESWL 
Results/ Conclusion by authors 
Krambeck 
29 
Retrospective 
cohort 
228 Non surgically 
managed 
urolithiasis 
patients 
Post: Patient reported New onset was noted in 16.8 % in 
eswl and 6.6% in the control group 
Kazemi 32 Retrospective 
cohort 
median not 
reported 
(range 180-
228) 
None Pre: medical chart review 
Post: Blood serum glucose 
levels, diagnosis of diabetes 
and prescribed anti-diabetic 
therapy 
Evidence that ESWL might be 
associated with an increase in 
fasting blood sugar levels 
 
 
Table 5 Studies suggesting no association between ESWL and an increase in the incidence of chronic kidney disease (CKD) 
First 
Author 
Design Follow-up 
time in 
months 
(mean or 
median) 
Reference 
group 
Identification 
of patients 
with KFD 
pre= before ESWL 
post= after ESWL 
Definition of 
KFD status 
Results/ Conclusion by authors 
Graff 33 Prospective 
cohort 
19 
(range 12-26) 
None Not reported Not reported During follow-up complete 
restoration was observed. 
Serious complications during 
follow-up were no encountered. 
Mays 5 Prospective 
cohort 
24 PNL Post: Reported 
by patients 
Not reported No evidence for an increase in 
the incidence of kidney function 
deterioration after ESWL 
compared to the PNL group 
Zanetti 34 Prospective 
cohort 
15 
(range 12-24) 
None Pre: Reported 
by 
physicians 
Post: Reported 
by 
physicians 
Ultrasound and 
blood serum 
creatinine levels 
No evidence for an increase in 
the incidence of kidney function 
deterioration after ESWL 
Simon 10 Retrospective 
cohort 
24 None Post: Reported 
by 
physicians 
Blood serum 
creatinine 
No evidence for an increase in 
the incidence of kidney function 
deterioration after ESWL 
Sarica 11 Prospective 
cohort 
33 
(range 30-39) 
None Post: 
Ultrasound and 
laboratory 
values 
Kidney size and 
parenchymal 
thickness 
“The long-term evaluation of our 
children proved the safety of this 
procedure” 
Traxer 13 Prospective 
cohort 
mean not 
reported 
(range 6-96) 
None Not reported Blood serum 
creatinine and 
parenchymal 
No parenchymal lesions were 
observed; values for serum 
creatinine levels were not 
damage reported. 
Perry 35 Retrospective 
cohort 
21 None Not reported Blood serum 
creatinine 
No evidence for an increase in 
the incidence of kidney function 
deterioration after ESWL 
Brinkmann 
16 
Prospective 
cohort 
45 None2 Pre: measured 
by physicians 
Post: measured 
by physicians 
Blood serum 
creatinine levels, 
kidney size 
measured by 
ultrasound 
No evidence for a damage  to 
growing kidneys 
El-Assmy 
36 
Retrospective 
cohort 
90 
(SD 52) 
None Not reported Not reported No evidence for an increase in 
the incidence of kidney function 
deterioration after ESWL 
El-Assmy 
20 
Retrospective 
cohort 
46 
(SD 42) 
(range 12-
192) 
None Post: measured 
by physicians 
Blood serum 
creatinine 
No evidence for an increase in 
the incidence of kidney function 
deterioration after ESWL  
“Safe in the long run” 
Eassa 19 Prospective 
cohort 
Mean 44 
(SD 14) 
(range 18-57) 
None Post: measured 
by physicians 
Blood serum 
creatinine 
No significant long-term effects 
on renal function  
Sato 21 Retrospective 
cohort 
204 
(range 132-
264) 
Ureteral 
stones treated 
with ESWL 
Pre: reported 
by patients 
Post: reported 
by patients 
Reporting 
hemodialysis 
No evidence for an increase in 
the incidence of kidney function 
deterioration after ESWL  
El-Nahas 
24 
Retrospective 
cohort 
62 
(SD 43) 
(range 25-
210) 
None measured by 
physicians 
Not reported no evidence for retardation of 
renal growth  
Yoo 37 Retrospective 
cohort 
20 
(SD 13) 
Non-ESWL 
treated 
urolithiasis 
patients 
Pre:  measured 
by physicians 
Post: measured 
by physicians 
Blood serum 
creatinine  
ESWL is associated with 
delayed deterioration of renal 
function in patients with a 
preexisting decrease in kidney 
function  
 
Table 6 Studies suggesting no association between ESWL and an increase in the incidence of infertility 
First 
Author 
Design Follow-up time 
in months 
(mean or median) 
Reference 
group 
Identification of 
patients with Fertility 
Status 
pre= before ESWL 
post= after ESWL  
Results/ Conclusion by authors 
Vieweg 
38 
Retrospective 
cohort 
38 
(range 9-68) 
None Patient reported No evidence for an increase in the 
incidence of infertility 
Erturk 39 Prospective 
cohort 
Not reported None Patient reported No evidence for an increase in the 
incidence of infertility 
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